지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.6
- 수록면
- 12 - 19 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: This study aimed to compare expression of human epidermal growth factor receptor (HER) family and insulin-like growth factor- 1 receptor (IGF-1R) before and after targeted therapy in HER-2 positive breast cancers.
Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced disease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test.
Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 (53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor responders, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demonstrated discordant results between before and after targeted therapy.
Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 targeted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy.
Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced disease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test.
Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 (53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor responders, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demonstrated discordant results between before and after targeted therapy.
Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 targeted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Expression of Growth Factor Receptor Family Before and After Targeted Therapy in Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Tissues
대한임상종양학회 학술대회지
2015 .02
-
Effect of Hormone Therapy on Long-term Outcomes of Patients with Human Epidermal Growth Factor Receptor 2-and Hormone Receptor-Positive Metastatic Breast Cancer: Real World Experience in China
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Receptor-Mediated Muscle Homeostasis as a Target for Sarcopenia Therapeutics
Endocrinology and Metabolism
2021 .01
-
Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
대한외과학회 학술대회 초록집
2017 .11
-
Expression of Estrogen and Progesterone Receptors in Papillary Thyroid Carcinoma in Korea
Cancer Research and Treatment
2021 .10
-
MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer
Journal of Breast Cancer
2017 .01
-
두경부암의 표적 치료제 저항성 기전
대한이비인후-두경부외과학회지
2016 .01
-
The Optimal Treatment Strategy in Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Breast Cancer Patients with 1-2 Suspicious Axillary Lymph Node on Breast MRI: Upfront Surgery vs.Neoadjuvant Chemotherapy?
대한외과학회 학술대회 초록집
2022 .05
-
The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase <sup>18</sup>F-FDG PET/CT
Nuclear medicine and molecular imaging : NMMI
2016 .01
-
Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Samples of Gastric and Gastro- Esophageal Junction Cancer
Journal of Gastric Cancer
2017 .03
-
Analysis of risk factors associated with survival in human epidermal growth factor receptor 2-positive ductal carcinoma in situ using Korean Breast Cancer Society Database
Annals of Surgical Treatment and Research
2021 .12
-
Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
Journal of Breast Cancer
2020 .01
-
The Effect of Progesterone Receptor Expression Level to Predict Prognosis of Estrogen Receptor Positive/ HER2 Negative Breast Cancer: A Single-center Prospective Cohort Study
대한외과학회 학술대회 초록집
2022 .11
-
전이성 유방암의 호르몬 치료
대한내과학회지
2017 .06
-
Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Journal of Pathology and Translational Medicine
2017 .07
-
Oncologic Effect of Oral Fluorouracil in Hormone Receptor-Negative T1a Node-Negative Breast Cancer Patients
Journal of Breast Disease
2016 .12
-
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer
영남의대학술지
2016 .01
-
Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma
Tuberculosis and Respiratory Diseases
2016 .01
-
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
Radiation oncology journal : ROJ
2016 .01
-
Characteristics of HER2-Positive Breast Cancer according to HER2 2+/Low or 3+/High Classification by Immunohistochemistry Assay: Study of 205 Cases Treated in a Single Center
Journal of Breast Disease
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2016-513-001624887